Figure S5 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

This is a In Vitro Study study.

Key Points

Targeting both bcl-xl and mcl-1 led to synergistic effects in AR-V7-expressing models of CRPC.
A-1331852, Navitoclax, and S63845 exhibited similar potency across 2D cultures and 3D spheroids, supporting their use together.
The study utilized different models of CRPC, indicating the potential for enhanced outcomes in treatment strategies.
Future research could explore the implications of these drugs on patient responses and therapeutic efficacy.

Assessment shows similar potency of A-1331852, Navitoclax, and S63845 in CRPC models, suggesting combined targeting may enhance treatment.

Figure S5 shows that A-1331852, Navitoclax, and S63845 have similar potency across 2D culture and 3D spheroids.

No takes yet. Share an insight, caveat, or question.

Brim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share